Antibe Therapeutics Inc (CVE:ATE) Director Michael Mcmillan purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, September 24th. The shares were purchased at an average cost of C$0.31 per share, for a total transaction of C$31,000.00.

ATE stock opened at C$0.37 on Wednesday. Antibe Therapeutics Inc has a fifty-two week low of C$0.08 and a fifty-two week high of C$0.79.

Antibe Therapeutics (CVE:ATE) last posted its quarterly earnings results on Wednesday, August 29th. The company reported C($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.02) by C$0.01. Antibe Therapeutics had a negative return on equity of 130.60% and a negative net margin of 94.01%. The business had revenue of C$2.54 million for the quarter, compared to the consensus estimate of C$2.30 million.

About Antibe Therapeutics

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

See Also: Trading Strategy Methods for Individual Investors

Insider Buying and Selling by Quarter for Antibe Therapeutics (CVE:ATE)

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.